Across TCGA pan-cancer cohorts, MIR1185-2 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated MIR1185-2 data layer compared with 1 for mutation status.
The strongest signal is observed in thymoma (THYM), where higher MIR1185-2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MIR1185-2 expression acts as an unfavorable survival marker, although some lineages such as LAML show a favorable association.
THYM, ESCA, and KIRC are the cancer types where MIR1185-2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.